Project Grant R44CA306447
Award Date 8/1/26
Completion Date 7/31/28
Dollars Obligated $1.1M
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Charlotte, NC 28223, USA
Similar Awards
- Federal Grant Award Summary Mucommune LLC received a $2.29 million Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective September 16, 2025, through August 31, 2027. The award supports development of an innovative in vivo chimeric antigen receptor T-cell (CAR-T) therapy platform targeting B7-H3 for treatment of pancreatic ductal adenocarcinoma (PDAC). Rather than the conventional labor-intensive and costly ex vivo approach of...
- Federal Grant Award Summary Georgetown University received a $401,115 Project Grant from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) effective May 7, 2026, with completion by April 30, 2028. The project focuses on developing targeted-nanoparticle strategies to improve therapeutic outcomes for pancreatic ductal adenocarcinoma (PDAC), a cancer with exceptionally poor prognosis (5-year survival rate of approximately 13%). The...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded University of California, Davis a $667,482 Project Grant on June 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop second-generation nanomedicine targeting treatment resistance in pancreatic ductal adenocarcinoma (PDAC). The primary deliverable is the development and preclinical validation of an autophagy inhibitor self-delivered nanodrug (AISN) based on a bisaminoquinoline...
- Federal Project Grant Summary The University of California, San Diego received a $411,206 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) awarded on May 14, 2026, with a completion date of April 30, 2028. This grant supports research and development of small molecule inhibitors targeting the proton-sensing receptor GPR68 as a novel therapeutic approach for pancreatic ductal adenocarcinoma (PDAC). The research addresses the critical...
- Federal Project Grant Award Summary Emory University's Office of Sponsored Programs received a $602,170 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) awarded June 2, 2026, with completion targeted for May 31, 2031. The research develops biomimetic migrating nanoparticles designed to target tumor stroma and neural invasion in pancreatic cancer treatment while reducing neuropathic pain. The core innovation involves a...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $400,614 through its Cancer Biology Research program (CFDA 93.396) to the University of Michigan, effective July 6, 2026, with a completion date of June 30, 2031. This Project Grant supports fundamental research investigating uridine metabolism as a therapeutic target in pancreatic ductal adenocarcinoma (PDA). The research addresses a critical gap in cancer treatment, as PDA is projected to become the second...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $407,726 to the University of Oklahoma Health Sciences Center on June 15, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate the role of the zinc finger protein ZC3H15 in pancreatic cancer pathogenesis and therapeutic response. The five-year project, extending through May 31, 2031, addresses the critical clinical need for improved pancreatic ductal adenocarcinoma (PDAC) treatment options...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded University of Massachusetts Medical School a $530,050 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective July 1, 2026, with completion targeted for June 30, 2031. This award supports the development of a multi-targeted nanoparticle-based immunotherapy platform designed to overcome immune suppressive barriers in pancreatic ductal adenocarcinoma (PDAC). The research focuses on engineering lipid...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Leland Stanford Junior University a $357,370 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on May 5, 2026, to support research on reprogramming inflammatory fibroblasts to overcome therapeutic resistance in pancreatic ductal adenocarcinoma (PDAC). The project, which will extend through April 30, 2031, focuses on understanding cancer-associated fibroblasts (CAFs)—specifically a unique...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $109,080 to The Trustees of Columbia University in the City of New York (Health Sciences Division) on September 1, 2025, under the Cancer Research Manpower program (CFDA 93.398) to support a Phase II investigator-initiated, multicenter randomized controlled trial (RCT) evaluating predictive markers of response to a novel immunotherapeutic approach in treatment-naive metastatic pancreatic adenocarcinoma (MPDA). The...